Implant abutment

Information

  • Patent Grant
  • 10848882
  • Patent Number
    10,848,882
  • Date Filed
    Monday, February 5, 2018
    6 years ago
  • Date Issued
    Tuesday, November 24, 2020
    4 years ago
Abstract
The present invention relates to a percutaneous implant abutment for bone anchored implant devices adapted to be anchored in the craniofacial region of a person, such as bone anchored hearing aids. The abutment comprises a skin penetration body having a skin contacting surface. The skin contacting surface has been modified.
Description
BACKGROUND
Field of the Invention

The present invention relates generally to bone anchored implant devices, and more particularly, to a percutaneous implant abutment for bone anchored implant devices adapted to be anchored in the craniofacial region of a person.


Related Art

There are a variety of medical devices that include a bone anchored implant device. An example of such medical devices is the, bone conduction hearing aid devices such as bone anchored hearing implants. An example of a bone anchored hearing implant is the Baha®, commercially available from Cochlear Bone Anchored Solutions AB in Goteborg, Sweden. The Baha® and other bone anchored implant devices comprise an external unit which transforms sound to mechanical vibrations which are conducted via the abutment and the fixture into the bone of the skull. The vibrations are transmitted mechanically via the skull bone directly to the inner ear of a person with impaired hearing and allows for the hearing organ to register the sound. A hearing aid device of the BAHA® type is connected to an anchoring element in the form of an implanted titanium screw installed in the bone behind the external ear. Sound is transmitted via the skull bone to the cochlea irrespective of a disease in the middle ear. The bone anchoring principle means that the skin is penetrated which makes the vibratory transmission very efficient.


This type of hearing aid device has been a revolution for the rehabilitation of patients with certain types of impaired hearing, but also as anti-stuttering means. It is very convenient for the patient and almost invisible with normal hair styles. It can easily be connected to the implanted titanium fixture by means of a bayonet coupling or a snap in coupling. One example of this type of hearing aid device is described in U.S. Pat. No. 4,498,461 and in SE 9702164-6 it is described a one-piece implant of this type, in which the fixture is integrated with a first coupling device. In WO 2005/037153 it is described how this type of hearing aid device can be used as an anti-stuttering device.


A well known problem with percutaneous implants is the infections and inflammation at the skin-implant interface. The infections are a result of bacterial colonization occurring at the area around the interface. There is generally a lack of integration of the skin to the implant which results in a gap between the two. This gap is unfortunately an ideal environment for the bacteria and if this zone is not properly managed, it is likely that an infection will occur. By creating an integration of the skin to the implant the adverse skin reactions associated with bone anchored percutaneous implants are expected to be reduced.


Creating integration between the skin and the implant requires that the implant is suitable for this purpose and that the soft tissue does not dissociate itself from the skin penetrating implant abutment by encapsulating the abutment in fibrous tissue.


In the field of dental implants it is previously known to use different types of abutments which penetrate the oral mucosa. However, it should be understood that there is a physiological difference between breaching the skin barrier compared to the oral mucosa. In the oral cavity the skin is not involved and there is another type of force situation. In contrast to dental implants the present invention relates to extraoral implants.


It is recognized that bone anchored percutaneously implants are subjected to mostly shear forces, while percutaneously implants which are not bone anchored are subjected to several other types of forces, such as pull and torsion. Such different types of forces are also mostly involved in dental applications. Mostly shear forces are especially the case for implants with inherent movements such as bone anchored hearing implants due to the generation of vibratory movements.


It is also recognized that the effect that the shear forces has on the skin leads to tissue damage not only from a mechanical point of view but, more importantly, an indirect biological reaction which leads to foreign body reaction or dissociation from the material (encapsulation of the implant by fibrous tissue, etc). Some reactions are acute and some are noticed after several weeks.


SUMMARY

In one aspect of the present invention, a percutaneous implant for bone anchored implant devices adapted to be anchored in the craniofacial region of a person is provided. The implant comprises: a screw-shaped bone anchoring element; an abutment, comprising: a skin penetration body having a skin contacting surface; and a biocompatible coating disposed on the skin contacting surface.





BRIEF DESCRIPTION OF THE DRAWINGS

Illustrative embodiments of the present invention will be described herein with reference to the accompanying figures, in which:



FIG. 1 illustrates an implant according to one embodiment of the present invention anchored in the bone in the craniofacial region of a person,



FIG. 2 illustrates an implant according to embodiments of the present invention for bone anchorage,



FIG. 3 is a LM picture of the interface between the skin and the contacting part of the implant abutment, and



FIG. 4 is a SEM picture of the surface structure of the skin contacting part of the implant abutment.





DETAILED DESCRIPTION

The present invention relates generally to bone anchored implant devices, and more particularly, to a percutaneous implant abutment for bone anchored implant devices adapted to be anchored in the craniofacial region of a person, such as bone anchored hearing aids. Implant devices of this type normally comprise a screw-shaped bone anchoring element (fixture) for permanent anchorage in the bone tissue and an abutment sleeve for skin penetration. The complete structure can either be in one piece or the skin penetrating abutment could be connected to the fixture prior, during or after the implantation procedure by means of a screw connection or the like.



FIG. 1 illustrates a percutaneous implant 1 in accordance with embodiments of the present invention anchored in the bone in the craniofacial region of a person. The implant is may be used for a bone anchored hearing aid or the like. The implant comprises a screw-shaped bone anchoring element (fixture) 2 for permanent anchorage in the bone tissue 3 and an abutment device 4 for skin 5 penetration. The complete structure can either be in one piece or the skin penetrating abutment 4 could be connected to the fixture prior, during or after the implantation procedure by means of a screw connection or the like. The screw-shaped anchoring element, the so-called fixture 2 is made of titanium which has a known ability to integrate with the surrounding bone tissue, so-called osseointegration. The fixture has a threaded part 2a which is intended to be installed into the skull bone and a flange 2b which functions as a stop when the fixture is installed into the skull bone. The apical part of the fixture has a known tapping ability with in this case three self-tapping edges 2c. A fixture of this type is described in the above-mentioned SE 0002627-8 and will therefore not be described in any detail here.


The skin penetrating part, the abutment 4 of the implant, comprises a substantially conical abutment sleeve. Conical abutment sleeves are previously known per se as separate components or as an integral part with the fixture, a one-piece implant. The abutment sleeve is provided with a first coupling part in order to cooperate with a second coupling part (not shown) by means of snap-in action or the like.


According to embodiments of the present invention the shear modulus of the skin contacting part of the percutaneous implant abutment 4 has been reduced. Preferably the shear modulus should be less than approximately 35 GPa.


Specifically, the shear modulus is reduced by a modification of the surface of the skin contacting part of the percutaneous implant abutment, illustrated by the structured abutment surface in FIG. 2. According to a preferred embodiment the surface of the skin contacting part of the percutaneous implant abutment is coated with a biocompatible polymer or a ceramic material with a thickness of approximately 0.001 μm to approximately-50 μm. The coating is applied in such a way that non-interconnected pores or crevices are created. Generally the coating should be applied in such a way that a structured surface such as a porous surface or a surface with indentations or a fibrous surface is obtained. A typical porous surface is illustrated by the SEM picture in FIG. 4.


The polymer coating is comparatively soft and decreases the shear stresses on the skin. In certain embodiments, a layer of a porous polymer is used for the coating with a thickness of about 30 nm. Such design is allowing the skin to heal into the polymer matrix.


Also a polymer containing a pharmaceutical drug that increases the production of extra-cellular matrix proteins in the soft tissue, such as collagen or keratin, might be used. The increased stability of the tissue increases the resistance to shear stress.


Also other types of materials might be used for increasing the skin tissue integration. Specifically, chemical substances such as pharmaceutical drugs and antioxidants, or biochemical substances such as proteins, biopolymers, growth factors, DNA, RNA or biominerals might be used. These substances are then associated to the implant with a purpose of increasing the amount of, or number of connections to extra cellular matrix proteins. Antibiotic, steroid or anti-inflammatory substances might also be used.


As an alternative to said coatings or substances, or in combination, a surface enlargement treatment can be provided to the surface of the skin contacting part of the percutaneous implant in order to increase the surface roughness. Such treatment can be achieved by using techniques that includes grit-blasting, polishing, micro-machining, laser treatment, turning, anodic oxidation, oxidation, chemical etching, sintering or plasma deposition of a titanium surface. Preferably such treatment should result in a 10% surface increase, compared to a conventional machined surface and a roughness value Sa of approximately 0.5 μm to approximately-10 μm, measured by means of White Light Interferometry.



FIG. 3 is a LM picture of the interface between the skin 5 and the contacting part of the implant abutment 4 of a polyurethane coated titanium material. The figure illustrates the situation after a healing period of 8 days and indicates a substantial integration of the abutment into the skin 5.



FIG. 4 is a SEM picture of the surface structure of the skin contacting part of the implant abutment having an anodically oxidized surface.


It should be understood that only that part of the abutment surface which is in contact with the skin need to be modified. Other parts of the abutment such as the lower and upper end surfaces, i.e. the surfaces connected to the fixture and the coupling device respectively, might have a conventional, machined and/or polished surface.


According to one embodiment of the present invention, the surface of the skin contacting part of the percutaneously implant abutment is coated with a biocompatible polymer with a thickness of approximately 0.001 μm-to approximately 50 μm. According to a another embodiment, the surface of the skin contacting part of the percutaneously implant abutment is coated with a ceramic material with a thickness of 0.001 μm-to approximately 50 μm.


According to another embodiment, a surface enlargement treatment has been provided to the surface of the skin contacting part of the percutaneously implant abutment. Preferably a 10% surface increase, compared to a conventional machined surface, is created resulting in a roughness value Sa of 0.5 μm-to approximately 10 μm.


It should be understood that there are percutaneous implant as such that are made of polymers (catheters etc) but they are not bone anchored and they are not exposed to the typical shear forces that are the case for implants with inherent movements such as bone anchored hearing implants due to the generation of vibratory movements.


An advantage of embodiments of the present invention is to provide an implant abutment in which the shear forces between the implant abutment and the skin have been reduced. This improves wound healing and integration around bone anchored percutaneous implants.


According to another feature of embodiments of the present invention, the shear modulus of the skin contacting part of the percutaneously implant abutment is reduced. Preferably the shear modulus should be less than approximately 35 GPa.


In certain embodiments, the implant design includes a flange or a skirt perpendicular to the abutment orientation in order to mechanically increase the surface area and stability and thereby also reduce the shear stress on the implant-skin interface. Also the implant design might include one or more retention grooves or waists. Otherwise, however, the abutment should be designed without any sharp edges or corners in order to simplify the surface modification procedure.


Further features and advantages of the present invention are described in commonly owned and co-pending U.S. Utility Patent Application entitled “VIBRATOR FOR BONE CONDUCTING HEARING DEVICES,” filed Nov. 24, 2009, which is a national stage application of PCT Application No. PCT/SE2008/000336, filed May 21, 2008; and commonly owned and co-pending U.S. Utility Patent Application entitled “ANCHORING ELEMENT” which is a national stage application under 35 USC § 371 (c) of PCT Application No. PCT/SE2008/000338, filed on May 21, 2008. The content of these applications are hereby incorporated by reference herein.


It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. Specifically it should be understood that any combinations of the said surface modifications could be used, e.g. using composites, structured ceramic coatings, polymer/pharmaceutical drug coatings, anodized flange etc. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims
  • 1. A percutaneous implant for a bone anchored implant device adapted to be anchored to a bone of a recipient, comprising: an abutment, including: a skin penetration body having a skin contacting surface; anda biocompatible coating disposed on the skin contacting surface,wherein the abutment is configured for interaction with an external unit which transforms sound to mechanical vibrations which are conducted to the abutment to evoke a hearing percept.
  • 2. The percutaneous implant of claim 1, wherein the biocompatible coating comprises a biocompatible polymer having a thickness of equal to or greater than approximately 0.001 micrometers.
  • 3. The implant according to claim 1, wherein the coating is configured to increase production of extra-cellular matrix proteins in soft tissue of the skin.
  • 4. A percutaneous abutment for a bone anchored implant device adapted to be anchored to a bone of a recipient, comprising: a skin penetration body having a skin contacting surface, wherein the abutment is configured such that the skin contacting surface is configured to integrate with recipient skin overlying the bone of the recipient, whereinat least one of: a threaded portion configured to be screwed into bone is mechanically attached to the abutment, wherein the threaded portion is a separate component from the abutment; orthe abutment is configured for interaction with an external unit which transforms sound to mechanical vibrations which are conducted to the abutment to evoke a hearing percept.
  • 5. The percutaneous abutment of claim 4 wherein: the abutment is configured to increase production of extra-cellular matrix proteins in soft tissue of the recipient skin, thereby integrating the abutment with the recipient skin overlying the bone of the recipient.
  • 6. The percutaneous abutment of claim 4 wherein: the abutment is coated with a ceramic.
  • 7. A percutaneous implant for a bone anchored implant device adapted to be anchored to a bone of a recipient, comprising: an abutment, including: a skin penetration body having a skin contacting surface; anda threaded portion configured to screw into bone, whereinthe implant includes a surface of a modified configuration, and the abutment is configured for interaction with an external unit which transforms sound to mechanical vibrations which are conducted to the abutment to evoke a hearing percept.
  • 8. The implant of claim 7, wherein: the modified configuration is a coating.
  • 9. The implant of claim 7, wherein: the implant is implanted in a recipient such that it is fixed to bone of the recipient, and wherein at least a portion of the implant is integrated with tissue of the recipient.
  • 10. The implant of claim 7, wherein: the implant is implanted in a recipient such that it is fixed to bone of the recipient; andthe modified surface has reduced shear forces between the abutment and skin of the recipient relative to that which would be the case in the absence of the modified surface.
  • 11. The implant device of claim 7, wherein: the modified configuration is that resulting from a surface enlargement treatment.
  • 12. The implant device of claim 7, wherein: the implant is implanted in a recipient such that it is fixed to bone of the recipient; andskin of the recipient overlying the bone of the recipient is healed into the surface of a modified configuration.
  • 13. The percutaneous implant of claim 1, wherein the biocompatible coating stops at a location at about where the implant would enter bone when anchored to bone.
  • 14. The implant of claim 7, wherein: the surface of the modified configuration includes at least one of porous surface features, indentations or fibrous surface features configured to integrate with recipient skin overlying the bone of the recipient.
  • 15. The percutaneous implant of claim 1, wherein the implant incudes a threaded portion configured to screw into bone, and wherein most of the biocompatible coating, based on surface area, is located away from the threaded portion.
  • 16. The percutaneous implant of claim 1, further comprising a threaded portion configured to be screwed into bone, wherein the threaded portion is a separate component from the abutment that is mechanically connected to the abutment.
  • 17. The percutaneous implant of claim 1, wherein the implant is implanted in a recipient and has been so implanted for eight (8) days, and wherein the abutment is substantially integrated into skin at the biocompatible coating.
  • 18. The implant of claim 7, wherein: the surface of the modified configuration is established by a surface enlargement treatment.
  • 19. The implant of claim 7, wherein: the surface of the modified configuration is established by laser treatment.
  • 20. The implant according to claim 1, wherein the biocompatible coating is configured to integrate with skin contacting the skin contacting surface.
  • 21. The implant according to claim 7, wherein the modified surface is configured to integrate with skin contacting the skin contacting surface.
Priority Claims (1)
Number Date Country Kind
0701244 May 2007 SE national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 14/685,048, filed Apr. 13, 2015, which is a continuation application of U.S. application Ser. No. 12/601,801, filed on May 21, 2010, now U.S. Pat. No. 9,005,202, which is a national stage application under 35 USC § 371 (c) of PCT Application No. PCT/SE2008/000337, entitled “IMPLANT ABUTMENT,” filed on May 20, 2008, which claims priority from Swedish Patent Application No. 0701244-6, filed on May 24, 2007. This application is related to commonly owned and co-pending U.S. Utility Patent Application entitled “VIBRATOR FOR BONE CONDUCTING HEARING DEVICES,” filed Nov. 24, 2009, which is a national stage application of PCT Application No. PCT/SE2008/000336, filed May 21, 2008. This application is also related to commonly owned and co-pending U.S. Utility Patent Application entitled “ANCHORING ELEMENT” which is a national stage application under 35 USC § 371 (c) of PCT Application No. PCT/SE2008/000338, filed on May 21, 2008. The entire disclosure and contents of the above applications are hereby incorporated by reference herein in their entirety.

US Referenced Citations (217)
Number Name Date Kind
3043000 Hatfield Jul 1962 A
3487403 Pihl Dec 1969 A
3573812 Pihl Apr 1971 A
D227118 Muraoka Jun 1973 S
3771685 Micallef Nov 1973 A
3801767 Marks Apr 1974 A
3987967 Kuznetsov et al. Oct 1976 A
4003521 Hess Jan 1977 A
4038990 Thompson Aug 1977 A
4052754 Homsy Oct 1977 A
4197840 Beck et al. Apr 1980 A
4199741 Paulet Apr 1980 A
4226164 Carter Oct 1980 A
4240428 Akhavi Dec 1980 A
4257936 Matsumoto et al. Mar 1981 A
4317969 Riegler et al. Mar 1982 A
D267541 Kanemitsu Jan 1983 S
4414701 Johnson Nov 1983 A
4498461 Hakansson Feb 1985 A
4596971 Hirabayashi et al. Jun 1986 A
4606329 Hough Aug 1986 A
4610621 Taber et al. Sep 1986 A
4612915 Hough et al. Sep 1986 A
4628907 Epley Dec 1986 A
4645504 Byers Feb 1987 A
4676772 Hooven Jun 1987 A
4696287 Hortmann et al. Sep 1987 A
4726378 Kaplan Feb 1988 A
4731718 Sheu Mar 1988 A
4736747 Drake Apr 1988 A
4818559 Hama et al. Apr 1989 A
RE32947 Dormer et al. Jun 1989 E
4868530 Ahs Sep 1989 A
4915628 Linkow et al. Apr 1990 A
4917504 Scott et al. Apr 1990 A
4918745 Hutchison Apr 1990 A
4920679 Sarles et al. May 1990 A
5014592 Zweig et al. May 1991 A
5015224 Maniglia May 1991 A
5026397 Aoki et al. Jun 1991 A
5049074 Otani et al. Sep 1991 A
5096763 Ogata et al. Mar 1992 A
5105811 Kuzma Apr 1992 A
5183056 Dalen et al. Feb 1993 A
5196710 Kalfaian Mar 1993 A
5314453 Jeutter May 1994 A
D348067 Lucey et al. Jun 1994 S
5456654 Ball Oct 1995 A
5456717 Zweymuller et al. Oct 1995 A
5549658 Shannon et al. Aug 1996 A
5554096 Ball Sep 1996 A
5603726 Schulman et al. Feb 1997 A
5624376 Ball et al. Apr 1997 A
5630835 Brownlee May 1997 A
5645580 Moaddeb et al. Jul 1997 A
5716407 Knapp et al. Feb 1998 A
5735790 Håkansson et al. Apr 1998 A
5749912 Zhang et al. May 1998 A
5775652 Crawshaw et al. Jul 1998 A
5785477 McGuffey et al. Jul 1998 A
5800336 Ball et al. Sep 1998 A
5857958 Ball et al. Jan 1999 A
5877664 Jackson, Jr. Mar 1999 A
5897486 Ball et al. Apr 1999 A
5906635 Maniglia May 1999 A
5913815 Ball et al. Jun 1999 A
5951601 Lesinski et al. Sep 1999 A
5971334 Crawshaw et al. Oct 1999 A
6011993 Tziviskos et al. Jan 2000 A
6040762 Tompkins Mar 2000 A
6073973 Boscaljon et al. Jun 2000 A
6138681 Chen et al. Oct 2000 A
6157278 Katznelson et al. Dec 2000 A
6157281 Katznelson et al. Dec 2000 A
6171229 Kroll et al. Jan 2001 B1
6175767 Doyle, Sr. Jan 2001 B1
6178079 Renger Jan 2001 B1
6178353 Griffith et al. Jan 2001 B1
6190305 Ball et al. Feb 2001 B1
6208235 Trontelj Mar 2001 B1
6208882 Lenarz et al. Mar 2001 B1
6217508 Ball et al. Apr 2001 B1
6219580 Faltys et al. Apr 2001 B1
6244142 Swanson Jun 2001 B1
6259951 Kuzma et al. Jul 2001 B1
6263230 Haynor et al. Jul 2001 B1
6272382 Faltys et al. Aug 2001 B1
6275736 Kuzma et al. Aug 2001 B1
6292678 Hall et al. Sep 2001 B1
6295472 Rubinstein et al. Sep 2001 B1
6295473 Rosar Sep 2001 B1
6308101 Faltys et al. Oct 2001 B1
6313551 Hazelton Nov 2001 B1
6348070 Teissl et al. Feb 2002 B1
6358281 Berrang et al. Mar 2002 B1
6401723 Garibaldi et al. Jun 2002 B1
6475134 Ball et al. Nov 2002 B1
6505062 Ritter et al. Jan 2003 B1
6506987 Woods Jan 2003 B1
6522909 Garibaldi et al. Feb 2003 B1
6542777 Griffith et al. Apr 2003 B1
6571676 Folsom et al. Jun 2003 B1
6589216 Abbott et al. Jul 2003 B1
6668065 Lee et al. Dec 2003 B2
6705985 Easter et al. Mar 2004 B2
6838963 Zimmerling et al. Jan 2005 B2
6857612 Goodbred Feb 2005 B2
D512416 Malaver Dec 2005 S
6991594 Holcomb Jan 2006 B2
7091806 Zimmerling et al. Aug 2006 B2
7190247 Zimmerling Mar 2007 B2
7200504 Fister Apr 2007 B1
7225028 Della Santina et al. May 2007 B2
7231252 Duncan et al. Jun 2007 B2
7338028 Zimmerling et al. Mar 2008 B2
7566296 Zimmerling et al. Jul 2009 B2
7610096 McDonald, III Oct 2009 B2
7642887 Zimmerling Jan 2010 B2
7647120 Della Santina et al. Jan 2010 B2
7695427 Kugler et al. Apr 2010 B2
7806693 Hurson Oct 2010 B2
7856986 Darley Dec 2010 B2
7976453 Zimmerling et al. Jul 2011 B2
7991477 McDonald, III Aug 2011 B2
8013699 Zimmerling Sep 2011 B2
8118725 Zimmerling et al. Feb 2012 B2
8211174 Park et al. Jul 2012 B2
8255058 Gibson et al. Aug 2012 B2
8260435 Johnson et al. Sep 2012 B2
8270647 Crawford et al. Sep 2012 B2
8340774 Hochmair et al. Dec 2012 B2
8469908 Asfora Jun 2013 B2
8515112 Crawford et al. Aug 2013 B2
8515544 Daly et al. Aug 2013 B2
8532783 Zimmerling et al. Sep 2013 B2
8634909 Zimmerling et al. Jan 2014 B2
8734475 Ekvall et al. May 2014 B2
8744106 Ball Jun 2014 B2
8758394 Zimmerling et al. Jun 2014 B2
8768480 Charvin Jul 2014 B2
8897475 Ball et al. Nov 2014 B2
8983102 Crawford et al. Mar 2015 B2
9005202 Andersson Apr 2015 B2
9022917 Kasic et al. May 2015 B2
RE45701 Zimmerling et al. Sep 2015 E
9144676 Gibson et al. Sep 2015 B2
9888329 Andersson Feb 2018 B2
20010021805 Blume et al. Sep 2001 A1
20010047175 Doubler et al. Nov 2001 A1
20020076071 Single Jun 2002 A1
20020099421 Goldsmith et al. Jul 2002 A1
20030120202 Gordon Jun 2003 A1
20030139782 Duncan Jul 2003 A1
20030171787 Money et al. Sep 2003 A1
20030176866 Westerkull Sep 2003 A1
20030181956 Duncan et al. Sep 2003 A1
20040012470 Zimmerling et al. Jan 2004 A1
20040059423 Barnes et al. Mar 2004 A1
20040132143 DeAngelis et al. Jul 2004 A1
20040167450 Buckman et al. Aug 2004 A1
20040204686 Porter et al. Oct 2004 A1
20040215164 Abbott et al. Oct 2004 A1
20040260361 Gibson Dec 2004 A1
20050001703 Zimmerling Jan 2005 A1
20050004629 Gibson et al. Jan 2005 A1
20050026113 Chen et al. Feb 2005 A1
20050062567 Zimmerling et al. Mar 2005 A1
20050106534 Gahlert May 2005 A1
20050113834 Breitenstien et al. May 2005 A1
20050142163 Hunter et al. Jun 2005 A1
20050159791 Daly et al. Jul 2005 A1
20050171579 Tasche et al. Aug 2005 A1
20060030905 Malaver Feb 2006 A1
20060050913 Westerkull Mar 2006 A1
20060093175 Westerkull May 2006 A1
20060184212 Faltys et al. Aug 2006 A1
20060241592 Myerson et al. Oct 2006 A1
20060244560 Zimmerling et al. Nov 2006 A1
20070009853 Pitulia Jan 2007 A1
20070126540 Zimmerling Jun 2007 A1
20070208403 Della Santina et al. Sep 2007 A1
20070270631 Nelson et al. Nov 2007 A1
20080221641 Hochmair Sep 2008 A1
20090069869 Stouffer et al. Mar 2009 A1
20090082817 Jinton et al. Mar 2009 A1
20090287278 Charvin Nov 2009 A1
20100249784 Andersson Sep 2010 A1
20110004278 Aghassian Jan 2011 A1
20110022120 Ball et al. Jan 2011 A1
20110264172 Zimmerling et al. Oct 2011 A1
20110295053 Ball Dec 2011 A1
20120022616 Garnham et al. Jan 2012 A1
20120022647 Leigh et al. Jan 2012 A1
20120029267 Ball Feb 2012 A1
20120172659 Ball et al. Jul 2012 A1
20120238799 Ball et al. Sep 2012 A1
20120296155 Ball Nov 2012 A1
20120323066 Cho et al. Dec 2012 A1
20120330378 Crawford et al. Dec 2012 A1
20130046131 Ball et al. Feb 2013 A1
20130046360 Gibson et al. Feb 2013 A1
20130053874 Ekvall et al. Feb 2013 A1
20130110198 Stoffaneller May 2013 A1
20140012070 Nagl et al. Jan 2014 A1
20140012071 Nagl et al. Jan 2014 A1
20140012349 Zimmerling Jan 2014 A1
20140121447 Kasic et al. May 2014 A1
20140213139 Ferguson Jul 2014 A1
20140275736 Ruppersberg et al. Sep 2014 A1
20140302741 Whittaker Oct 2014 A1
20140343626 Thenuwara et al. Nov 2014 A1
20150087892 Tourrel et al. Mar 2015 A1
20150157778 Ishiyama et al. Jun 2015 A1
20160008596 Gibson et al. Jan 2016 A1
20160144170 Gibson et al. May 2016 A1
20160361537 Leigh et al. Dec 2016 A1
20170312503 Leigh et al. Nov 2017 A1
Foreign Referenced Citations (12)
Number Date Country
1068052 Dec 1979 CA
2485716 Apr 2005 CA
0367354 May 1990 EP
414579 Aug 1934 GB
2266045 Oct 1993 GB
H06192852 Jul 1994 JP
9855049 Dec 1998 WO
0197718 Dec 2001 WO
0209622 Feb 2002 WO
02056637 Jul 2002 WO
2004091432 Oct 2004 WO
2005037153 Apr 2005 WO
Non-Patent Literature Citations (4)
Entry
Daniel Rutter, “Comparison: Lightwave 2000, 3000, 4000, Illuminator and Pocket-Bright, and Petzl Tikka” pp. 1-30, Feb. 14, 2002. http://www.dansdata.com/ledlights7.htm.
Med-El, “Magnetic Resonance Imaging (MRI),” believed to be available in Jan. 2016.
D. Cuda et al., “Focused tight dressing does not prevent cochlear implant magnet migration under 1.5 Tesla MRI,” believed to be available in Jan. 2016.
International Search Report for PCT/SE2008/000337 dated Jul. 16, 2008.
Related Publications (1)
Number Date Country
20180234780 A1 Aug 2018 US
Continuations (2)
Number Date Country
Parent 14685048 Apr 2015 US
Child 15888628 US
Parent 12601801 US
Child 14685048 US